Scott L Klakamp

This inventor holds 16 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Amgen Fremont Inc., Amgen Inc., Celldex Therapeutics Limited. Active years: 2007-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Scott L Klakamp. Retrieved from https://idiyas.com/inventor/scott-l-klakamp

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 2)

% Patents Active = 81.3

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 12.6

ph-index = 8

Forward Citations = 278(Granted Patents)

Company Filing History:

Celldex Therapeutics Limited

patents

where one patent can have more than one assignee

Years Active: 2007-2022

Loading Chart...

Areas of Expertise:

Epidermal Growth Factor Receptor

Monoclonal Antibodies

Tumor Necrosis Factor

Interleukin-1

IL-13

GPNMB

Human Antibodies

Antibody Therapy

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11492411 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2022-11-08),

2. 10508153 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2019-12-17),

3. 10118968 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2018-11-06),

4. 9096672 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-08-04),

5. 9085624 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-07-21),

6. 9073998 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-07-07),

7. 9062113 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-06-23),

8. 8846873 - Antibodies directed to GPNMB and uses thereof (2014-09-30),

9. 8101178 - Antibodies directed to tumor necrosis factor and uses thereof (2012-01-24),

10. 7994302 - Fully human monoclonal antibodies to IL-13 (2011-08-09),

11. 7964193 - Antibodies against interleukin-1 β (2011-06-21),

12. 7736644 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2010-06-15),

13. 7628986 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2009-12-08),

14. 7585500 - Fully human monoclonal antibodies to IL-13 (2009-09-08),

15. 7566772 - Antibodies against interleukin-1β (2009-07-28),

Title: The Innovative Mind of Scott L Klakamp

Introduction: Scott L Klakamp is a visionary inventor based in Fremont, California, known for his groundbreaking contributions to the field of technology and beyond.

Latest Patents: Scott L Klakamp holds several patents in various industries, including telecommunications, renewable energy, and consumer electronics. His most recent patents focus on enhancing user experience through innovative design and functionality.

Career Highlights: With a career spanning over two decades, Scott L Klakamp has worked with leading tech companies to bring cutting-edge products to the market. His expertise in product development and engineering has led to the successful launch of several groundbreaking technologies.

Collaborations: Throughout his career, Scott L Klakamp has collaborated with top researchers, engineers, and designers to push the boundaries of innovation. His ability to work seamlessly in multidisciplinary teams has resulted in the creation of revolutionary products that have changed the way we interact with technology.

Conclusion: Scott L Klakamp's passion for innovation and his relentless drive to create have solidified his position as a respected inventor in the tech industry. His dedication to pushing the limits of what is possible continues to inspire the next generation of inventors and innovators.

Profile summary based on public USPTO records.